ProHealth me-cfs Vitamin and Natural Supplement Store and Health
Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help

|
|

Trending News

10 Celebrities with ME/CFS

The Brain Boosting and Fatigue Fighting B-12

Severe ME/CFS - New Clinical Study

Norwegian ‘Woulds’ (and ‘Wouldn’ts’): The ME/CFS Survey

Altered immune response to exercise in patients with chronic fatigue syndrome/myalgic encephalomyeli...

Altered Distribution of Lymphocyte Populations in Chronic Fatigue Syndrome Patients

Simmaron Foundation’s Immunology Workshop: The Forefront of Diagnosing and Treating ME/CFS

VIDEO: Julia Newton Talks About Neurocognitive problems in ME/CFS

“Flowers” in the blood: A novel paired erythrocyte arrangement in a patient with chronic fatigue syn...

Considerations in establishing a post-mortem brain and tissue bank for the study of myalgic encephal...

 
Print Page
Email Article

GLYX-13 looks like lucky number for depression prone

  [ 9 votes ]   [ Discuss This Article ]
www.ProHealth.com • December 9, 2012


Effect size within 24 hours after a single dose was nearly double the effect size seen with most other antidepressant drugs after four to six weeks of repeated dosing.

A first-of-its-kind antidepressant drug discovered by a Northwestern University professor and now tested in a 12-site phase IIa trial on adults who have failed other antidepressant therapies has been shown to alleviate symptoms within hours, have good safety, and produce positive effects that last for about seven days from a single dose. (A 20-site phase IIb trial now underway is studying the effect of repeated doses.)

The novel therapeutic targets brain receptors responsible for learning and memory - a very different approach from existing antidepressants. The new drug and others like it also could be helpful in treating other neurological conditions, including schizophrenia, bipolar disorder, anxiety and Alzheimer’s disease.

The compound, called GLYX-13, is the result of more than two decades of work by Joseph Moskal, PhD, research professor of biomedical engineering at Northwestern. On Dec 3, the journal Neuropsychopharmacology published a paper describing some of the research underlying the clinical development of GLYX-13. And on Dec 6 Prof Moskal presented the results of the recent trial to members of the American College of Neuropsychopharmacology at their annual meeting in Hollywood, FL.

“Our study showed that this compound is capable of eliciting a robust and rapid antidepressant effect without the typical side effects seen with other drugs that also modulate the NMDA receptor,” says Dr. Moskal, who is founder and chief scientific officer of the Evanston, IL-based biotechnology company Naurex Inc., which conducted the clinical study. (Northwestern has granted to Naurex exclusive licensing of the intellectual property rights related to the therapeutics Dr. Moskal developed while at the University, and has a small equity position in Naurex.)

GLYX-13 works by modulating the NMDA (N-methyl-D-aspartate) receptor in the brain, as do current NMDA receptor antagonists such as ketamine, but GLYX-13 does not have their serious and limiting side effects, such as hallucinations and schizophrenia-like effects. (An antagonist is a substance that inhibits the physiological action of another.)

Dr. Moskal and his team have figured out a new way to target the NMDA receptors that maintains the positive antidepressant properties while eliminating the negative side effects.

In clinical trials administered at 12 sites across the country, a single dose of GLYX-13 resulted in significant reductions in depression symptoms among subjects who had shown little improvement with previous drugs. (Subjects had failed treatment with one or more antidepressant agents.)

The positive effects of GLYX-13 were evident within 24 hours and lasted an average of seven days.

The effect size, a measure of the magnitude of the drug’s antidepressant efficacy, at both these times after a single dose was nearly double the effect size seen with most other antidepressant drugs after four to six weeks of repeated dosing.

Side effects of GLYX-13 were mild to moderate and were consistent with those observed in subjects receiving a placebo.

GLYX-13 is a four-amino acid peptide that modulates one of a large family of glutamate receptors, the NMDA (N-methyl-D-aspartate) receptor, in the brain. NMDA receptors play a key role in regulating synaptic plasticity - the quality of the connection between neurons - and thus are important in regulating learning and memory functions.

GLYX-13 is currently administered intravenously, but Naurex is now working on an oral drug with similar properties and potential, Dr. Moskal says.

Further, he says, it is his hope that these positive GLYX-13 results and the research efforts of his team and colleagues will help shepherd in more research and grant support for studying the role of the glutamate-mediated processes in neuropsychiatric disorders.

“While the results we are seeing with GLYX-13 are very encouraging, I believe the most important research is yet to come,” he adds. “We have only scratched the surface of the therapeutic potential of the glutamatergic system.”

GLYX-13 currently is undergoing a phase IIb clinical trial at 20 sites across the United States. This trial is evaluating repeated doses of the drug.

__

Source: Based on Northwestern University press release by Megan Fellman with contributions by Sarah Ostman, Dec 6, 2012




Discuss This Article Post a Comment 




[ Be the first to comment on this article ]




 
Free Chronic Fatigue Syndrome and Fibromyalgia Newsletters
Subscribe to
Our FREE
Newsletter
Subscribe Now!
Receive up-to-date ME/CFS & Fibromyalgia treatment and research news
 Privacy Guaranteed  |  View Archives

Featured Products

MitoQ® MitoQ®
Powerful Antioxidant Support to Mitochondria
B-12 Extreme™ B-12 Extreme™
The Most Potent Vitamin B-12 on Earth
Hydroxocobalamin Extreme™ Hydroxocobalamin Extreme™
The B-12 your brain needs for detox & sharpness
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium

Natural Remedies

The Remarkable Benefits of Reishi Medicinal Mushrooms The Remarkable Benefits of Reishi Medicinal Mushrooms
Protect Against Sun-Induced Skin Aging From The Inside Out Protect Against Sun-Induced Skin Aging From The Inside Out
Dreaming of a Good Night's Sleep? Dreaming of a Good Night's Sleep?
Running on Empty? Fuel Up with NADH Running on Empty? Fuel Up with NADH
Reversing Neurodegeneration with a New Magnesium Compound Reversing Neurodegeneration with a New Magnesium Compound

FIBROMYALGIA RESOURCES
What is Fibromyalgia?
Fibromyalgia 101
Fibromyalgia Symptoms
Fibromyalgia Treatments
| CFS RESOURCES
What is CFS?
ME/CFS 101
ME/CFS Symptoms
ME/CFS Treatments
| FORUMS
Fibromyalgia
ME/CFS
ADVANCED MEDICAL LABS
WHOLESALE  |  AFFILIATES
GUARANTEE
CONTACT US
PRIVACY
RSS
SITE MAP
ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus
Credit Card Processing